January 8, 2024Open Access

Assessment of the U.S. Food and Drug Administration's risk evaluation and mitigation strategy (REMS) for prasugrel (EFFIENT): A narrative review

Q: What does this research mean for the field?

The FDA's risk evaluation and mitigation strategy (REMS) for prasugrel is inadequate in quality and impact, indicating a need for improvement in post-approval safety activities. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

Key Result

The assessment indicates that the FDA's REMS for prasugrel is inadequate in quality and impact, suggesting a need for improvement in post-approval safety activities.

Structured PICO

Intervention

FDA's risk evaluation and mitigation strategy (REMS) for prasugrel

The evaluation of the prasugrel REMS highlights the need to improve the quality and impact of FDA post-approval activities to maximize drug safety.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

The prasugrel REMS consisted of passive educational materials whose adequacy was evaluated using highly limited, one-time, cross-sectional surveys. Our assessment adds to evidence suggesting the importance of improving the quality and impact of the FDA's post-approval activities to maximize drug safety.

Bookmark

View Full Paper

Cite This Study

Metkus et al. (Mon,) reported a other. The assessment indicates that the FDA's REMS for prasugrel is inadequate in quality and impact, suggesting a need for improvement in post-approval safety activities.

synapsesocial.com/papers/6967d0580ea1492ff3f9b893 https://doi.org/https://doi.org/10.1016/j.ahjo.2024.100359

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper